Georgia

Georgia is now one of the more interesting “watch, don’t overstate” jurisdictions. HB 382 is structurally important because it anticipates future FDA/DEA action on crystalline polymorph psilocybin, but it does not create present-day lawful non-research access. Georgia remains a state where future federal drug approval could trigger a state-law consequence faster than in many peers.###

HB 717 is equally important, though for a different reason. It treats psychedelic-assisted treatment and therapy as a clinic-regulation issue and pushes implementation into the Georgia Composite Medical Board. That positions Georgia to regulate ketamine/esketamine clinics and potentially future federally lawful psychedelic therapies, while still leaving classical psychedelic access tied to federal approval or research permissions.###

Emory is the clearest research anchor. Emory’s Centre for Psychedelics and Spirituality and related research pages list the COMP005 psilocybin study for treatment-resistant depression and the Usona 301 psilocybin study for major depressive disorder. Emory also joined the NIH-funded INSPIRE network to study psychedelics for chronic pain in older adults, with early work including psilocybin and LSD.###

Georgia also appears in sponsor-led multicentre work beyond Emory. ClinicalTrials.gov lists an Atlanta site, Peachford Hospital–Atlanta Behavioral Research, for a CYB003 deuterated psilocin-analogue study in major depressive disorder. This shows that Georgia’s trial footprint is broader than one academic centre, though access remains trial-bound rather than programme-based.###

HB 717 is the central implementation story. The Georgia Composite Medical Board must adopt rules by the end of 2026, and the law points toward clinic licensure from mid-2027. In other words, Georgia now has real implementation machinery, but it is machinery for regulating clinics, not for opening a state psilocybin market in 2026.###

That distinction matters operationally. Researchers and providers should watch rulemaking on staffing, training, airway-management and clinic standards. Investors and service operators should treat Georgia as an emerging compliance jurisdiction for ketamine/esketamine and future federally lawful psychedelic therapies, not as a state-regulated psilocybin-service state.###

Emory is the dominant verified institutional node in Georgia’s ecosystem, combining psychiatry, spiritual-health co-therapy infrastructure and active study recruitment. That makes Georgia more of a research-and-future-clinic-regulation jurisdiction than a decriminalisation or ballot-measure jurisdiction.###

The second important node is the Atlanta private research-site ecosystem, exemplified by Peachford Hospital–Atlanta Behavioral Research appearing on ClinicalTrials.gov for a psychedelic study. The Georgia Composite Medical Board is also now part of the practical ecosystem because it will own the forthcoming clinic rulebook.###

Over the next 12–24 months, Georgia’s centre of gravity will be implementation of HB 717. Stakeholders should expect detailed board rulemaking on clinic operations, staffing and administration standards. That could make Georgia one of the more concretely regulated ketamine/esketamine clinic markets in the South.###

For classical psychedelics, the outlook stays research-led. Georgia’s most meaningful near-term patient-access changes would likely come from trial availability or from future federal approvals that activate state-law provisions such as HB 382, rather than from broad state-level decriminalisation or service-centre legislation.###